Vimarsana
Biggest News Aggregation in the World

Page 18 - Dan Budwick News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dan Budwick. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dan Budwick Today - Breaking & Trending Today

Apogee Therapeutics to Participate in Upcoming August Investor Conferences - Vimarsana News

Apogee Therapeutics to Participate in Upcoming August Investor Conferences

SAN FRANCISCO and WALTHAM, Mass., Aug. 02, 2023 -- Apogee Therapeutics, Inc. , a biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive...

Alector to Host Mid-Year Earnings Conference Call - Vimarsana News

Alector to Host Mid-Year Earnings Conference Call

SOUTH SAN FRANCISCO, Calif., July 27, 2023 -- Alector, Inc. , a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on...

Apogee Therapeutics, Inc. Announces Pricing of Upsized - Vimarsana News

Apogee Therapeutics, Inc. Announces Pricing of Upsized

SAN FRANCISCO and WALTHAM, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company advancing...

Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome - Vimarsana News

Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome

-- Collaboration combines Prime Medicine’s Prime Editing platform with Cimeio Therapeutics’ Shielded Cell and Immunotherapy Pairs™ (SCIP™) platform -- -- Aim to reduce toxicity of conditioning regimens and introduce new therap...

Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions - Vimarsana News

Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions

Structure Therapeutics announced that clinical and preclinical data from its oral GLP-1 receptor agonist GSBR-1290 program will be presented at the upcoming American Diabetes Association (ADA) 83rd Scientific Sessions